http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021162000-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5038bbee3600f108fd0df37a794d9cb2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6937 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 |
| filingDate | 2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e63677fe770579e2b975117faacc8a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c1833e63549760c5d8cfc91fa98299c |
| publicationDate | 2021-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2021162000-A1 |
| titleOfInvention | Pcsk9 inhibitory polypolypeptides and methods of use |
| abstract | The present invention relates to PCSK9 inhibitors and methods of use thereof. Specifically, the invention relates to PCSK9 cell-based assay, PCSK9 inhibiting polypeptides and derivatives thereof. The invention includes pharmaceutical compositions comprising a PCSK9 inhibitor polypeptide together with a pharmaceutically acceptable carrier and method for treating cardiovascular disorders, hyperlipidemia, inflammatory diseases or inflammatory response to infection. |
| priorityDate | 2015-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 849.